Asset profile
PRI-002
Small molecule
Evidence outlook · lead readout
NCT06182085 · Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease, Early Onset
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06182085: The study randomized 304 participants to two PRI-002 dose groups or placebo and used quadruple masking of participants, caregivers, investigators, and outcome assessors. Its primary efficacy measure was the clinical CDR-SB outcome, but whether the primary comparison was met cannot be determined because results are not available.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.